1, so we have an ongoing pII study on T817MA connected to

New Post Public Reply Private Reply Replies (0) Message Board
freegriff
1, so we have an ongoing pII study on T817MA connected to Stern, fully funded by Toyoma, thats having problems getting good data, getting patients to finish trials, using imaging etc. approx 400 people in this trial, with numerous sub study add ons


2. and the we have the huge A4 study starting soon, run by Stern and others, fully funded by Eli Lilly ( where we got Dr. Trzepacz from), the NIH (JC), and philanthropies. http://www.bu.edu/alzresearch/ http://www.amarantus.com/about/alzheimers-dis...ostics-sab

10,000 individuals needed in US Canada and AUS for 1,000 to be enrolled in study =$$$ on screening and $$$ on continual evaluation for the MONTHLY infusions. 10,000x $1,000 = $10mill. 1,000 x let's say quarterly x4 x $1,000. This has got to be in the revenue range of $10-20mill plus. This trial gives monthly infusions for 3.5 years, records evaluations from an observer/friend once a week, and could be huge if we get in on it. I went through the screening questions, and "Are you willing to have your health monitored throughout the study with the following assessments?...e. Blood and urine tests" is a question, though admittedly that's likely just to make sure the infusions are killing you. http://a4study.org/screener/

if solanezumab is succesfful and Lympro is involved, it will become one of, or the paired diagnostic. $$$

http://a4study.org/about/

please note, Dr. Stern has an "exciting" presentation February 24 Alzheimer's Disease & Dementia 2015: Reasons for Hope

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Hims & Hers Health: Navigating Demand for Weight Loss Solutions

Updated Category News Views 340

Hims & Hers Health Navigates Demand Challenges This Thursday, a noteworthy update emerged when the FDA announced that the supply shortage affecting a prominent medication, tirzepatide injection from Eli Lilly And Co., has been resolved. This glucagon-like peptide 1 (GLP-1) medication, recognized by its branding as Mounjaro and Zepbound, had been in short supply since 2022...

Continue Reading
Unlock Daily Passive Income with Leading Cloud Mining Firm

Updated Category News Views 408

Unlock Daily Passive Income with CRYPTO MINING FIRM In today's fast-paced cryptocurrency landscape, the prospect of compounding offers investors an exciting avenue for growth. By strategically reinvesting earned interests, such as yield farming profits or staking rewards, individuals can significantly amplify their portfolio's value over time. Enter CRYPTO MINING FIRM, a...

Continue Reading
Spotify's Leadership Transition: What It Means for Investors

Updated Category News Views 226

Spotify's New Direction with Leadership Changes In a significant reshaping of its leadership structure, Spotify Technology S.A. (NYSE: SPOT) has announced that founder and CEO Daniel Ek will transition to the role of executive chairman next year. This change marks the first substantial restructuring of the company’s leadership in nearly twenty years. Co-presidents...

Continue Reading
Mercer International Inc. Achieves Robust EBITDA Growth in 2024

Updated Category News Views 287

Mercer International Inc. Sees Impressive Growth in 2024 Mercer International Inc. (NASDAQ: MERC) has reported significant financial results for the fourth quarter and the year ended in 2024. The company achieved an Operating EBITDA of $99.2 million in Q4, a substantial increase from $50.5 million in the previous quarter and a notable leap from $21.1 million in the same...

Continue Reading
Ping An's Remarkable Growth and Strategic Innovations in 2025

Updated Category News Views 435

Ping An Maintains Steady Growth Amid Economic Challenges In a rapidly changing economy, Ping An Insurance (Group) Company of China, Ltd. has demonstrated remarkable resilience and growth. Despite facing fluctuations in domestic demand and market stability issues, the Group reported a substantial increase in overall performance for the year 2024. Financial Performance...

Continue Reading